Table 1.
Biochemical and virologic response to tenofovir disoproxil fumarate at year 7 (week 336)
| By HBeAg status | All | ||
|---|---|---|---|
| HBeAg-negativea | HBeAg-positiveb | ||
| HBV DNA < 69 IU/mL [% (n/N)] | |||
| LTE-TDFc | 77.3 (269/348) | 60.3 (149/247) | 70.3 (418/595) |
| On treatmentd | 99.3 (271/273) | 99.4 (159/160) | 99.3 (430/433) |
| HBV DNA < 29 IU/mL [% (n/N)] | |||
| LTE-TDFc | 77.1 (269/349) | 60.3 (149/247) | 70.1(418/596) |
| On treatmentd | 99.3 (271/273) | 99.4 (159/160) | 99.3 (430/433) |
| ALT normalization [% (n/N)] | |||
| LTE-TDFc | 64.6 (210/325) | 46.9 (113/241) | 57.1 (323/566) |
| On treatmentd | 83.5 (213/255) | 74.2 (115/155) | 80.0 (328/410) |
| HBeAg loss [% (n/N)] | – | 54.5 (84/154) | – |
| HBeAg seroconversion [% (n/N)] | – | 39.6 (61/154) | – |
| HBsAg loss [K-M % (95 % CI)] | – | 11.8 (8.1, 16.9) | – |
| HBsAg seroconversion [K-M % (95 % CI)] | – | 9.7 (6.4, 14.6) | – |
ALT alanine aminotransferase, CI confidence interval, HBeAg hepatitis B e-antigen, HBV hepatitis B virus, K–M Kaplan–Meier
aHBeAg-negative patients were enrolled in Study 102
bHBeAg-positive patients were enrolled in Study 103
cIn the long-term evaluation–TDF only (LTE-TDF) analysis, patients with missing data or emtricitabine added to their treatment regimen were counted as failures
dIn the on-treatment analysis, patients with missing data were excluded and patients with emtricitabine added to their treatment regimen were included in the analysis